CompletedNCT00208156
Mifepristone for recurring psychotic symptoms in major depression
About this title
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Read the official source — NCT00208156Researchers studied Mifepristone to find out how it affected psychotic symptoms in people with depression.
Medication studyAges 18–75United States
Understand this study
What did researchers investigate?
Researchers studied Mifepristone to find out how it affected psychotic symptoms in people with depression.
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- San Diego and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 87
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00208156
- Official title
Show the full official title
An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Get this study by email
Recruitment & locations
CompletedSan Diego · Atlanta · Las Vegas
10 more locations
- Clementon
- Newark
- Toms River
- Glen Oaks
- Lawrence
- Oklahoma City
- Philadelphia
- Bellaire
- Richmond
- Bellevue
Questions about this study
What did researchers investigate?
Researchers studied Mifepristone to find out how it affected psychotic symptoms in people with depression.
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Mifepristone.
Who was this study for?
Listed age limits: 18 years to 75 years.
